6 results match your criteria: "Crawley (G.J.H.); and Stanford University School of Medicine[Affiliation]"
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Circ Cardiovasc Qual Outcomes
May 2017
From the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.O., D.W., W.S.J., M.R.P.); Department of Statistics, North Carolina State University, Raleigh (D.H.); Mount Sinai Medical Center, New York, NY (J.L.H.); Department of Cardiovascular Medicine, Hospital of the University of Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston (D.E.S.); University of Edinburgh and Royal Infirmary of Edinburgh, Scotland, United Kingdom (K.A.A.F.); School of Medicine and Pharmacology, University of Western Australia, Crawley (G.J.H.); and Stanford University School of Medicine, CA (K.W.M.).
Systolic Blood Pressure and Vascular Disease in Men Aged 65 Years and Over: The HIMS (Health in Men Study).
Hypertension
June 2017
From the Western Australian Centre for Health & Ageing, Centre for Medical Research (B.L., K.A.M., L.F., O.P.A.), School of Medicine and Pharmacology (B.L., B.B.Y., K.A.M., L.F., O.P.A., G.J.H.), School of Surgery (P.E.N.), and School of Psychiatry and Clinical Neurosciences (O.P.A.), University of Western Australia, Crawley; Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, United Kingdom (B.L., S.L.); Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Australia (J.G.); The Department of Vascular and Endovascular Surgery, The Townsville Hospital, Australia (J.G.); Department of Endocrinology and Diabetes, Fiona Stanley and Fremantle Hospitals, Perth, Australia (B.B.Y.); Department of Geriatric Medicine, Royal Perth Hospital, Australia (L.F.); and Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.).
There is uncertainty about the relation between blood pressure and vascular disease at older age. We assessed the association of systolic blood pressure (SBP) and major vascular events in a prospective cohort study of 7564 men aged 65 to 94 years, recruited in 1996-1999 from the general population in Perth, Western Australia. SBP was measured at baseline and again at resurvey in 2001-2004.
View Article and Find Full Text PDFTreatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
Circulation
March 2017
From Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (S.M.L., C.B.F., A.S.H., Y.L., J.P.P., M.R.P.); Division of Cardiology, University of British Columbia, Vancouver, Canada (C.B.F.); Department of Cardiovascular Medicine, University of Münster, Germany (G.B.); Stanford University School of Medicine, CA (K.W.M.); Massachusetts General Hospital and Harvard Medical School, Boston (D.E.S.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Cardiovascular Institute, Mount Sinai Medical Center, NY (J.L.H.); School of Medicine and Pharmacology, The University of Western Australia, Crawley (G.J.H.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Janssen Research and Development LLC, Raritan, NJ (C.C.N.); University of Cincinnati College of Medicine, OH (R.C.B.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".
Circulation
July 2016
From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Circulation
January 2016
From Duke Clinical Research Institute, Durham, NC (J.P.P., A.S.H., M.R.P.); Duke Heart Center, Duke University Medical Center, Durham, NC (J.P.P., J.B.W., M.R.P.); University of Cincinnati College of Medicine, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Whippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, WA (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, Palo Alto, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
Background: Patients with atrial fibrillation (AF) often take multiple medications.
Methods And Results: We examined characteristics and compared adjusted outcomes between rivaroxaban and warfarin according to number of concomitant baseline medications and the presence of combined cytochrome P450 3A4 and P-glycoprotein inhibitors in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study. At baseline, 5101 patients (36%) were on 0 to 4 medications, 7298 (51%) were on 5 to 9, and 1865 (13%) were on ≥ 10.
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
J Am Heart Assoc
March 2015
Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.).
Background: In the ROCKET AF (Rivaroxaban-Once-daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) trial, marked regional differences in control of warfarin anticoagulation, measured as the average individual patient time in the therapeutic range (iTTR) of the international normalized ratio (INR), were associated with longer inter-INR test intervals. The standard Rosendaal approach can produce biased low estimates of TTR after an appropriate dose change if the follow-up INR test interval is prolonged. We explored the effect of alternative calculations of TTR that more immediately account for dose changes on regional differences in mean iTTR in the ROCKET AF trial.
View Article and Find Full Text PDF